Form 4: SpringWorks Therapeutics Executive Receives Stock and Option Grants
SEC Form 4 Filing
Michael Nofi, Chief Accounting Officer of SpringWorks Therapeutics, received grants of restricted stock units and stock options on January 10, 2025.
Summary
- Michael Nofi, the Chief Accounting Officer of SpringWorks Therapeutics, received a grant of 6,929 restricted stock units (RSUs) and an option to purchase 20,246 shares of common stock on January 10, 2025.
- The RSUs vest in three tranches: 33% on January 10, 2026, 33% on January 10, 2027, and 34% on January 10, 2028, contingent upon continued service.
- The stock options vest in 48 equal monthly installments following January 10, 2025, also subject to continued service.
- Following these transactions, Nofi directly owns 30,623 shares of SpringWorks Therapeutics common stock and options to purchase 20,246 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive due to the incentive structure.
Positives
- The grants of RSUs and stock options align the executive's interests with those of the shareholders, incentivizing continued service and performance.
- The vesting schedules encourage long-term commitment from the Chief Accounting Officer.
Industry Context
Grants of stock options and restricted stock units are common practices in the pharmaceutical industry to attract, retain, and incentivize key executives. These grants align executive compensation with company performance and shareholder value.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation tools for executives in publicly traded biotech companies.
- Companies like Amgen, Gilead, and Vertex typically use similar equity-based compensation plans to incentivize their leadership teams.
- The vesting schedules described are also typical, designed to retain talent over a multi-year period.
Stakeholder Impact
- Shareholders: The grants align executive interests with shareholder value.
- Employees: The grants can boost morale by demonstrating investment in leadership.
- Executive: The grants provide a financial incentive for continued service and performance.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction: Grant of RSUs and stock options. |
| 01/10/2026 | First vesting date for 33% of the RSUs. |
| 01/10/2027 | Second vesting date for 33% of the RSUs. |
| 01/10/2028 | Final vesting date for 34% of the RSUs. |
| 01/10/2035 | Expiration date of the stock options. |
| 01/14/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.